Compare SITM & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SITM | VTRS |
|---|---|---|
| Founded | 2003 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 18.7B |
| IPO Year | 2019 | 2019 |
| Metric | SITM | VTRS |
|---|---|---|
| Price | $681.42 | $16.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $405.00 | $13.50 |
| AVG Volume (30 Days) | 483.2K | ★ 10.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 57.53 | N/A |
| EPS | ★ 0.47 | 0.05 |
| Revenue | $326,660,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $49.65 | $4.41 |
| Revenue Next Year | $27.77 | $1.96 |
| P/E Ratio | $1,587.74 | ★ $324.60 |
| Revenue Growth | ★ 61.16 | N/A |
| 52 Week Low | $204.81 | $9.43 |
| 52 Week High | $901.81 | $18.39 |
| Indicator | SITM | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 44.30 |
| Support Level | $657.38 | $15.82 |
| Resistance Level | $763.31 | $16.54 |
| Average True Range (ATR) | 42.97 | 0.51 |
| MACD | 15.68 | -0.14 |
| Stochastic Oscillator | 68.22 | 20.12 |
SiTime Corp is a provider of Precision Timing solutions to the international electronics industry, providing the timing functionality needed for electronics to operate reliably and correctly. The Company's products are designed to address a wide range of applications across a broad array of end markets. The Company operates a fabless business model and leverages its international network of distributors to address the end markets it serves. The Company operates in one reportable segment related to the design, development, and sale of silicon timing systems solutions. It operates in Hong Kong, Taiwan, the United States, Singapore, and other regions, with the majority of revenue coming from Hong Kong.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.